Intranasal delivery of MEK Inhibitors to target paediatric gliomas

点击翻译按钮获取中文摘要

University of Nottingham researchers have been working on developing novel formulations with excipients designed to enhance penetration to obtain novel delivery systems across 1) the eye to treat diseases in the posterior segment and 2) the skin to obtain systemic delivery without requiring injection. The work so far has determined that it is possible to modify the structure of excipients to selectively enhance the penetration of drugs across different tissues. The excipients can deliver >70% of the API from a topical formulation into the body. The research question we aim to answer in this project is whether this technology will work to deliver therapeutics from a nasal spray across the blood brain barrier. This is key especially for paediatric patients. Having the ability to treat paediatric patients with brain cancers such as gliomas intranasally rather than using systemic delivery (which patients struggle to tolerate) has the potential to significantly improve patient wellbeing and medicine compliance. It would also give greater flexibility around dosing.